Log in

$246.61 Million in Sales Expected for Omega Healthcare Investors Inc (NYSE:OHI) This Quarter

Last updated on Wednesday, September 16, 2020 | 2020 MarketBeat

Wall Street analysts predict that Omega Healthcare Investors Inc (NYSE:OHI) will post sales of $246.61 million for the current fiscal quarter, according to Zacks Investment Research. Four analysts have issued estimates for Omega Healthcare Investors' earnings, with the highest sales estimate coming in at $253.40 million and the lowest estimate coming in at $227.70 million. Omega Healthcare Investors posted sales of $233.20 million in the same quarter last year, which indicates a positive year over year growth rate of 5.8%. The firm is expected to report its next quarterly earnings report on Tuesday, November 3rd.

According to Zacks, analysts expect that Omega Healthcare Investors will report full-year sales of $991.68 million for the current financial year, with estimates ranging from $921.60 million to $1.02 billion. For the next financial year, analysts expect that the company will report sales of $993.05 million, with estimates ranging from $898.70 million to $1.03 billion. Zacks' sales averages are a mean average based on a survey of research firms that follow Omega Healthcare Investors.

Omega Healthcare Investors (NYSE:OHI) last issued its earnings results on Wednesday, August 5th. The real estate investment trust reported $0.43 earnings per share for the quarter, missing the consensus estimate of $0.75 by ($0.32). Omega Healthcare Investors had a net margin of 39.17% and a return on equity of 9.22%.

A number of research analysts have commented on OHI shares. JMP Securities started coverage on Omega Healthcare Investors in a research report on Monday, June 8th. They set a "market perform" rating for the company. Citigroup upped their price target on Omega Healthcare Investors from $25.00 to $30.00 and gave the company a "neutral" rating in a research report on Thursday, July 2nd. Truist upped their price target on Omega Healthcare Investors from $32.00 to $34.00 in a research report on Monday. Raymond James lowered Omega Healthcare Investors from a "strong-buy" rating to an "outperform" rating and set a $34.00 price target for the company. in a research report on Monday, August 3rd. Finally, Smith Barney Citigroup started coverage on Omega Healthcare Investors in a research report on Monday, July 13th. They set a "neutral" rating for the company. Three analysts have rated the stock with a sell rating, six have given a hold rating and five have assigned a buy rating to the stock. The stock presently has a consensus rating of "Hold" and an average price target of $33.63.

Shares of OHI stock opened at $32.93 on Wednesday. The stock has a market capitalization of $7.47 billion, a PE ratio of 19.15, a P/E/G ratio of 4.15 and a beta of 0.85. Omega Healthcare Investors has a 1-year low of $13.33 and a 1-year high of $45.22. The business has a 50-day moving average of $31.87 and a 200 day moving average of $30.43. The company has a debt-to-equity ratio of 1.25, a current ratio of 3.35 and a quick ratio of 3.35.

Hedge funds have recently bought and sold shares of the stock. The Manufacturers Life Insurance Company increased its position in Omega Healthcare Investors by 2.1% during the 1st quarter. The Manufacturers Life Insurance Company now owns 312,941 shares of the real estate investment trust's stock valued at $8,305,000 after buying an additional 6,457 shares in the last quarter. Commonwealth Equity Services LLC raised its holdings in shares of Omega Healthcare Investors by 11.0% in the first quarter. Commonwealth Equity Services LLC now owns 184,897 shares of the real estate investment trust's stock worth $4,907,000 after buying an additional 18,382 shares during the period. Hancock Whitney Corp bought a new position in shares of Omega Healthcare Investors in the first quarter worth about $259,000. Rhumbline Advisers raised its stake in shares of Omega Healthcare Investors by 9.1% during the first quarter. Rhumbline Advisers now owns 669,367 shares of the real estate investment trust's stock valued at $17,765,000 after acquiring an additional 56,083 shares in the last quarter. Finally, M&T Bank Corp grew its stake in Omega Healthcare Investors by 48.2% in the first quarter. M&T Bank Corp now owns 19,585 shares of the real estate investment trust's stock worth $520,000 after purchasing an additional 6,369 shares in the last quarter. 71.63% of the stock is owned by institutional investors.

About Omega Healthcare Investors

Omega is a real estate investment trust that invests in the long-term healthcare industry, primarily in skilled nursing and assisted living facilities. Its portfolio of assets is operated by a diverse group of healthcare companies, predominantly in a triple-net lease structure. The assets span all regions within the US, as well as in the UK.

Recommended Story: Most Volatile Stocks

Get a free copy of the Zacks research report on Omega Healthcare Investors (OHI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Omega Healthcare Investors (NYSE:OHI)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]

7 Great Biotech Stocks That Don’t Depend on a Coronavirus Cure

Biotech stocks are some of the most volatile for investors to include in their portfolio. And that volatility can be hard to predict. Biotech companies don’t have a firm correlation with the overall economy. And what can add to the challenge is that many of these companies are small-cap companies that are not well-known names.

These small biotech stocks may shoot higher based on a vaccine or drug candidate that gets national attention. But these small-cap stock also reflect the adage of letting the buyer beware. Because the stark reality for many investors is that the vast majority of these treatments never make it past clinical trials. And that means that a stock that goes up rapidly can move down just as fast. We’re seeing that right now with the multitude of companies that are competing in the race towards a vaccine and/or treatment for Covid-19 and the novel coronavirus that causes the disease. And if you’ve been good at timing the market, you could have made some good money on some of these candidates.

Of course, if you held the stock too long, you could have lost your shirt as well.

That doesn’t mean however that buy and hold investors should avoid the biotech sector altogether. There are still some attractively priced small-cap biotech companies that are working on treatments for a range of conditions that provide them with a large addressable base. And we’ve identified seven of these stocks in this special presentation.

View the "7 Great Biotech Stocks That Don’t Depend on a Coronavirus Cure".

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.